Itopride Does Not Increase Appetite in GERD Treatment
Itopride is a prokinetic agent used to improve gastric motility and reduce reflux symptoms in GERD, but there is no evidence that it increases appetite as a therapeutic effect. The drug works by antagonizing dopamine D2 receptors and inhibiting acetylcholinesterase to enhance gastrointestinal motility, not by stimulating appetite 1, 2.
Mechanism and Clinical Use
Itopride functions as an add-on therapy to proton pump inhibitors (PPIs) in GERD management. When combined with PPIs, it provides synergistic benefits by:
- Improving gastric emptying and reducing reflux episodes
- Alleviating symptoms like heartburn, regurgitation, nausea, and postprandial fullness
- Enhancing treatment efficacy in PPI-refractory cases 1, 2
Evidence on Symptom Relief
Recent studies demonstrate that itopride as adjunctive therapy significantly improves multiple GERD symptoms, but appetite stimulation is not among the documented effects:
- A 2024 retrospective study of 140 patients showed greatest improvement in heartburn, nausea, and laryngopharyngeal symptoms when itopride (150 mg/day) was added to PPI therapy 1
- Another 2024 prospective study found marked reduction in postprandial fullness, early satiety, and bloating—symptoms that might improve eating tolerance but do not represent appetite stimulation 2
Standard GERD Management Context
The American Gastroenterological Association guidelines emphasize that PPIs remain the cornerstone of GERD treatment (Grade A recommendation), with no mention of prokinetic agents like itopride in standard management algorithms 3. In fact, metoclopramide (another prokinetic) receives a Grade D recommendation against its use in GERD 3.
The 2022 AGA Clinical Practice Update reinforces PPI therapy as first-line treatment, with dose escalation or switching to more potent acid suppressants for inadequate response 4. Prokinetic agents are not included in these evidence-based recommendations.
Important Clinical Distinction
If a patient experiences improved eating after starting itopride for GERD, this likely reflects relief from obstructive symptoms (nausea, early satiety, postprandial fullness) rather than true appetite stimulation. The drug addresses mechanical and motility issues that may have been limiting food intake, not the neurohormonal pathways that regulate hunger and appetite.
Practical Considerations
- Itopride shows favorable safety profile with minimal adverse effects in GERD studies 1, 2
- It may be considered as adjunctive therapy in PPI-refractory GERD, though this is not guideline-supported
- Any perceived increase in food intake should be attributed to symptom relief rather than appetite enhancement
- Standard GERD management should prioritize PPI optimization before considering prokinetic add-on therapy 4